Free Trial
NASDAQ:BMRN

BioMarin Pharmaceutical (BMRN) Stock Price, News & Analysis

BioMarin Pharmaceutical logo
$57.23 +0.53 (+0.93%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$57.24 +0.02 (+0.03%)
As of 11/13/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About BioMarin Pharmaceutical Stock (NASDAQ:BMRN)

Advanced

Key Stats

Today's Range
$56.35
▼
$57.39
50-Day Range
$54.38
▼
$66.53
52-Week Range
$49.26
▼
$70.98
Volume
1.47 million shs
Average Volume
2.53 million shs
Market Capitalization
$11.09 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$87.22
Consensus Rating
Moderate Buy

Company Overview

BioMarin Pharmaceutical is a biotechnology company focused on developing and commercializing medicines for people with rare genetic diseases. Its work includes research, clinical development, manufacturing and distribution of therapies for conditions that often have limited treatment options.

The company’s marketed treatments address disorders including phenylketonuria, mucopolysaccharidosis, late-infantile neuronal ceroid lipofuscinosis, achondroplasia and hemophilia A. Its products include Kuvan and Palynziq for phenylketonuria, Vimizim for Morquio A syndrome, Brineura for CLN2 disease, Voxzogo for achondroplasia and Roctavian for hemophilia A.

Founded in 1997 and headquartered in San Rafael, California, BioMarin serves patients and healthcare providers in the United States and international markets, including Europe. The company’s operations combine a focus on rare-disease research with the development and global commercialization of specialized therapies.

AI Generated. May Contain Errors.

BioMarin Pharmaceutical Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
84th Percentile Overall Score

BMRN MarketRank™: 
4.21854478592 of 5 stars

BioMarin Pharmaceutical scored higher than 84% of companies evaluated by MarketBeat, and ranked 58th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    BioMarin Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 3 strong buy ratings, 15 buy ratings, 6 hold ratings, and 1 sell rating.

  • Upside Potential

    BioMarin Pharmaceutical has a consensus price target of $87.22, representing about 52.4% upside from its current price of $57.23.

  • Amount of Analyst Coverage

    BioMarin Pharmaceutical has been the subject of 15 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about BioMarin Pharmaceutical's stock forecast and price target.
  • Earnings Growth

    Earnings for BioMarin Pharmaceutical are expected to grow by 133.64% in the coming year, from $2.20 to $5.14 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of BioMarin Pharmaceutical is -572.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of BioMarin Pharmaceutical is -572.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Growth Ratio

    BioMarin Pharmaceutical has a PEG Ratio of 0.76. PEG Ratios below 1 indicate that a company could be undervalued.

  • Price to Book Value per Share Ratio

    BioMarin Pharmaceutical has a P/B Ratio of 1.77. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    7.34% of the float of BioMarin Pharmaceutical has been sold short.
  • Short Interest Ratio / Days to Cover

    BioMarin Pharmaceutical has a short interest ratio ("days to cover") of 5.77.
  • Change versus previous month

    Short interest in BioMarin Pharmaceutical has recently increased by 17.20%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    BioMarin Pharmaceutical does not currently pay a dividend.

  • Dividend Growth

    BioMarin Pharmaceutical does not have a long track record of dividend growth.

  • News Sentiment

    BioMarin Pharmaceutical has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 9 news articles for BioMarin Pharmaceutical this week, compared to 8 articles on an average week.
  • Search Interest

    Only 14 people have searched for BMRN on MarketBeat in the last 30 days. This is a decrease of -18% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added BioMarin Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, BioMarin Pharmaceutical insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    0.68% of the stock of BioMarin Pharmaceutical is held by insiders.

  • Percentage Held by Institutions

    98.71% of the stock of BioMarin Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about BioMarin Pharmaceutical's insider trading history.
Receive BMRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioMarin Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BMRN Stock News Headlines

BioMarin Pharmaceutical (BMRN) Receives a Buy from Evercore ISI
Unbelievable…Congress is About to Do What?
Jim Rickards, former advisor to the CIA, the Pentagon and the White House, says a key turning point in Washington is set to take place by November 30th. He believes it could create one of the most chaotic environments in America's history. He predicts those who understand what's happening could do very well over the next 12-18 months, while others may face steep losses. Rickards outlines the five steps he recommends.tc pixel
BioMarin Updates Vosoritide Study in Rare Growth Disorder
See More Headlines

BMRN Stock Analysis - Frequently Asked Questions

BioMarin Pharmaceutical's stock was trading at $59.43 at the start of the year. Since then, BMRN stock has decreased by 3.7% and is now trading at $57.23.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) posted its earnings results on Monday, November, 2nd. The biotechnology company reported $0.23 earnings per share for the quarter, topping analysts' consensus estimates of ($0.05) by $0.28. The company's revenue was up 32.0% on a year-over-year basis.
Read the conference call transcript
.

Top institutional investors of BioMarin Pharmaceutical include First Trust Advisors LP (0.99%), Assenagon Asset Management S.A. (0.69%), ARGA Investment Management LP (0.38%) and Edmond DE Rothschild Holding S.A. (0.37%). Insiders that own company stock include Jean Jacques Bienaime, Henry J Fuchs, Jeffrey Robert Ajer, Charles Greg Guyer, Brian Mueller, George Eric Davis, Gregory R Friberg, Cristin Hubbard and Erin Burkhart.
View institutional ownership trends
.

Shares of BMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that BioMarin Pharmaceutical investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Gilead Sciences (GILD), Salesforce (CRM), Vertex Pharmaceuticals (VRTX) and Regeneron Pharmaceuticals (REGN).

Company Calendar

Last Earnings
11/02/2026
Today
11/15/2026
UBS Global Biopharma Conference 2026
11/16/2026
Jefferies Global Healthcare Conference
11/17/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:BMRN
CIK
1048477
Employees
3,221
Year Founded
1997

Price Target and Rating

High Price Target
$114.00
Low Price Target
$60.00
Potential Upside/Downside
+52.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
25 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.10)
Trailing P/E Ratio
N/A
Forward P/E Ratio
11.13
P/E Growth
0.76
Net Income
$348.90 million
Net Margins
-0.52%
Pretax Margin
1.19%
Return on Equity
5.58%
Return on Assets
3.51%

Debt

Debt-to-Equity Ratio
0.56
Current Ratio
2.44
Quick Ratio
1.32

Sales & Book Value

Annual Sales
$3.66 billion
Price / Sales
3.03
Cash Flow
$2.88 per share
Price / Cash Flow
19.87
Book Value
$32.30 per share
Price / Book
1.77

Miscellaneous

Outstanding Shares
193,695,000
Free Float
192,378,000
Market Cap
$11.09 billion
Optionable
Optionable
Beta
0.21

Social Links

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

This page (NASDAQ:BMRN) was last updated on 11/13/2026 by MarketBeat.com Staff.
From Our Partners